Perspective Therapeutics (CATX) Net Margin (2010 - 2023)

Perspective Therapeutics (CATX) has 14 years of Net Margin data on file, last reported at 105.73% in Q4 2023.

• For the quarter ending Q4 2023, Net Margin changed N/A year-over-year to 105.73%; the trailing twelve-month figure through Dec 2023 stood at 1070.09% (changed N/A YoY), and the FY2023 full-year result was 631.31%, changed N/A from the prior year.
• Net Margin grew to 105.73% in Q4 2023, from 35.88% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 105.73% in Q4 2023 to a low of 108.0% in Q2 2023.
• A 5-year average of 44.28% and a median of 40.75% in 2019 frame the typical range for Net Margin.
• Across the five-year window, Net Margin soared 9022 bps in 2019 and plunged 6963 bps in 2023, its largest moves.
• Tracing CATX's Net Margin over 5 years: stood at 40.75% in 2019, then advanced by 10 bps to 36.8% in 2020, then plunged by 55 bps to 56.96% in 2021, then slumped by 84 bps to 105.06% in 2022, then surged by 201 bps to 105.73% in 2023.
• Business Quant data shows CATX's Net Margin at 105.73% in Q4 2023, 35.88% in Q3 2023, and 108.0% in Q2 2023.